Abbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors

Simply Wall St.

06/07

In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2641769271"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2641769271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2641769271?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","is_english":true,"pubTime":"2026-06-07 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641769271","market":"hk","top_or_hot":-1,"title":"Abbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors","media":"Simply Wall St.","content":"<div>\n<p>In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-is-up-64-after-european-approval-of\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-07 21:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-is-up-64-after-european-approval-of><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-is-up-64-after-european-approval-of\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0266013472.USD","symbol_name":"AXA WF - Framlington Longevity Economy A Cap USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-is-up-64-after-european-approval-of","article_id":"2641769271","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-is-up-64-after-european-approval-of","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641769271","pubTimestamp":1780839029,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its first-of-its-kind dual glucose‑ketone continuous monitoring systems, while awaiting U.S. FDA clearance.\nThe combination of alarming national trends in DKA-related hospitalizations and Abbott’s dual-analyte sensor positions the company to address a critical gap in diabetes care.\nWe’ll now examine...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4588":"碎股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4568":"美国抗疫概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","SG9999002232.USD":"Allianz Global High Payout USD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","SG9999002224.SGD":"Allianz Global High Payout SGD","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","BK4581":"高盛持仓","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","ABT":"雅培","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4504":"桥水持仓","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","ABT.AU":"Abundant Produce","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0122379950.USD":"贝莱德世界健康科学A2","BK4566":"资本集团","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","EPV":"ProShares UltraShort MSCI Europe","LU0058720904.USD":"联博国际健康护理基金A","BK4082":"医疗保健设备","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4592":"伊斯兰概念","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC"},"translate_title":"欧洲批准双葡萄糖酮传感器后，雅培实验室(ABT)股价上涨6.4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPV":1.5,"ABT.AU":1.5,"ABT":1.5},"content_text":"In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its first-of-its-kind dual glucose‑ketone continuous monitoring systems, while awaiting U.S. FDA clearance. The combination of alarming national trends in DKA-related hospitalizations and Abbott’s dual-analyte sensor positions the company to address a critical gap in diabetes care. We’ll now examine how Abbott’s dual glucose‑ketone technology and focus on earlier DKA detection may influence its broader investment narrative. Find 49 companies with promising cash flow potential yet trading below their fair value.AdvertisementAbbott Laboratories Investment Narrative RecapTo own Abbott, you need to believe in its diversified healthcare model and its ability to keep innovating in core franchises like diabetes care and diagnostics. The latest dual glucose ketone data and CE Mark for Libre Duo align with that story, but they do not change the near term focus on stabilizing Diagnostics after COVID testing declines or the key risk around pricing pressure in diabetes devices. Among recent announcements, the American Cancer Society’s reaffirmation of Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options is especially relevant. It underlines Abbott’s broader bet on clinically validated, guideline supported tools that can sustain growth beyond Libre, even as competitive and reimbursement pressures build around continuous glucose monitoring. However, while Libre Duo may help differentiation today, competitive bidding and rising CGM competition in the US could still pressure pricing in ways investors should be aware of... Read the full narrative on Abbott Laboratories (it's free!)Abbott Laboratories’ narrative projects $59.6 billion revenue and $9.5 billion earnings by 2029. This requires 9.7% yearly revenue growth and a $3.2 billion earnings increase from $6.3 billion today.Uncover how Abbott Laboratories' forecasts yield a $117.29 fair value, a 29% upside to its current price.Exploring Other PerspectivesABT 1-Year Stock Price Chart Six members of the Simply Wall St Community currently see Abbott’s fair value between US$117.29 and US$140.18, well above the recent share price. You should weigh those views against risks like intensifying CGM competition and pricing pressure that could influence Abbott’s ability to convert its innovation pipeline into sustained financial performance.Explore 6 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 54% more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Abbott Laboratories research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}